Jackson Creek Investment Advisors LLC Cuts Position in CareDx, Inc (NASDAQ:CDNA)

Jackson Creek Investment Advisors LLC lowered its stake in shares of CareDx, Inc (NASDAQ:CDNA) by 3.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 44,029 shares of the company’s stock after selling 1,358 shares during the period. Jackson Creek Investment Advisors LLC owned about 0.08% of CareDx worth $943,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Inceptionr LLC acquired a new stake in shares of CareDx in the 4th quarter worth approximately $240,000. Raymond James Financial Inc. acquired a new stake in CareDx in the fourth quarter valued at $3,694,000. Charles Schwab Investment Management Inc. increased its position in shares of CareDx by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 511,922 shares of the company’s stock valued at $10,960,000 after buying an additional 12,442 shares in the last quarter. Plato Investment Management Ltd increased its position in shares of CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company’s stock valued at $116,000 after buying an additional 1,370 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of CareDx by 907.5% in the 4th quarter. US Bancorp DE now owns 17,168 shares of the company’s stock worth $368,000 after buying an additional 15,464 shares in the last quarter.

CareDx Stock Up 0.1 %

Shares of CareDx stock opened at $18.92 on Friday. The firm has a market cap of $1.01 billion, a PE ratio of -7.01 and a beta of 1.87. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84. The business’s fifty day moving average is $22.56 and its two-hundred day moving average is $24.87.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm had revenue of $86.58 million for the quarter, compared to analyst estimates of $84.56 million. Equities research analysts anticipate that CareDx, Inc will post -0.9 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CDNA. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a report on Wednesday, February 26th. Wells Fargo & Company raised shares of CareDx from an “underweight” rating to an “equal weight” rating and dropped their price objective for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. HC Wainwright reduced their target price on CareDx from $26.00 to $25.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Finally, Stephens reiterated an “overweight” rating and set a $40.00 target price on shares of CareDx in a report on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $31.83.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.